Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6358441 | 0.89 | MAPT (0.60) | MEN1KMT2AMAPTTSHRPOLB | |
| SCHEMBL27660170 | 0.85 | TP53 (0.51) | MEN1KMT2AMAPTTSHRNPC1 | |
| SCHEMBL6103175 | 0.83 | POLB (0.66) | MAPTTSHRPOLBLMNAALDH1A1 | |
| SCHEMBL11096709 | 0.81 | ALDH1A1 (0.55) | MEN1KMT2AMAPTPOLBNPC1 | |
| SCHEMBL446340 | 0.81 | SLC6A3 (0.60) | KMT2AMAPTTSHRNPC1LMNA | |
| SCHEMBL2946505 | 0.79 | SLC6A3 (0.68) | MEN1KMT2AMAPTTSHRNPC1 | |
| SCHEMBL1095516 | 0.79 | MEN1 (0.64) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL29812845 | 0.79 | MEN1 (0.64) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL28337798 | 0.79 | KMT2A (0.60) | MEN1KMT2AMAPTPOLBNPC1 | |
| SCHEMBL3077888 | 0.78 | RAB9A (0.62) | KMT2AMAPTTSHRNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1117409-B1 | BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-BLOCKERS FOR THE TREATMENT OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM | AVENTIS PHARMA GMBH (DE) | 2005-01-26 | — | — | EP | disclosed |
| EP-1401419-A1 | BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT OF SEPTIC SHOCK AND SIRS | Aventis Pharma Deutschland GmbH (DE) | 2004-03-31 | — | — | EP | disclosed |
| US-20030083385-A1 | Use of benzenesulfonyl (thioureas or ure as) for treating of septic shock or gene ralized inflammatory syndrome | GERLACH UWE (DE) | 2003-05-01 | — | — | US | disclosed |
| WO-2003000244-A1 | BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT OF SEPTIC SHOCK AND SIRS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-01-03 | — | — | WO | disclosed |
| US-6414030-B1 | 1-((5-(2-(5-TERT-BUTYL-2-METHOXYBENZAMIDO)ETHYL)-2-METHOXYPHEN YL)-SULFONYL)-3-METHYLTHIOUREA AND PROPANOLOL FOR EXAMPLE | AVENTIS PHARMA DEUTSCHLAND, GMBH (DE) | 2002-07-02 | — | — | US | disclosed |
| US-20020082300-A1 | USE OF BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT AND PROPHYLAXIS OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM AND USE OF BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-RECEPTOR BLOCKERS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-06-27 | — | — | US | disclosed |
| EP-1117409-A2 | USE OF BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM | Aventis Pharma Deutschland GmbH (DE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000015204-A2 | USE OF BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT AND PROPHYLAXIS OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM AND USE OF BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-RECEPTOR BLOCKERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082300-A1 | USE OF BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT AND PROPHYLAXIS OF DYSFUNCTIONS OF THE AUTONOMOUS NERVOUS SYSTEM AND USE OF BENZENESULFONYL(THIO)UREAS IN COMBINATION WITH BETA-RECEPTOR BLOCKERS | UTS2R, TST, SIGMAR1 | MEN1 4394/4885KMT2A 3432/4885MAPT 2852/4885 |
| US-20030083385-A1 | Use of benzenesulfonyl (thioureas or ure as) for treating of septic shock or gene ralized inflammatory syndrome | UTS2R, EIF2S1, TST | MEN1 4700/4885KMT2A 3903/4885MAPT 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.